AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 175 filers reported holding AMYLYX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $49,233,265 | -53.2% | 2,688,873 | -44.8% | 1.64% | -46.0% |
| Q2 2023 | $105,130,433 | -40.6% | 4,873,919 | -19.2% | 3.04% | -41.8% |
| Q1 2023 | $177,056,455 | -21.3% | 6,034,644 | -0.9% | 5.23% | -17.2% |
| Q4 2022 | $224,963,904 | +46.0% | 6,088,333 | +11.3% | 6.32% | +41.3% |
| Q3 2022 | $154,038,000 | +125.9% | 5,472,033 | +54.6% | 4.47% | +109.3% |
| Q2 2022 | $68,188,000 | +260.0% | 3,540,408 | +140.2% | 2.14% | +463.6% |
| Q1 2022 | $18,942,000 | – | 1,474,107 | – | 0.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,756,050 | $35,415,000 | 3.44% |
| Boxer Capital, LLC | 2,200,000 | $28,270,000 | 1.45% |
| Alpha Wave Global, LP | 617,220 | $7,931,000 | 0.72% |
| Ikarian Capital, LLC | 396,654 | $5,097,000 | 0.67% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 768,603 | $9,877,000 | 0.58% |
| Ikarian Capital, LLC | 250,000 | $3,213,000 | 0.42% |
| 683 Capital Management, LLC | 677,714 | $7,685,000 | 0.41% |
| Perceptive Advisors | 1,474,107 | $18,942,000 | 0.38% |
| VIKING GLOBAL INVESTORS LP | 7,170,536 | $92,141,000 | 0.37% |
| Rock Springs Capital Management LP | 998,307 | $12,828,000 | 0.32% |